Trials / Completed
CompletedNCT01189032
Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry Eye
Dose-Response Study of DE-089 Ophthalmic Solution in Patients With Dry Eye -Late Phase II Confirmatory Study-
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 320 (actual)
- Sponsor
- Santen Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- —
Summary
Dose response related to efficacy and safety of DE-089 ophthalmic solution are examined in patients with dry eye, using a multicenter, randomized, double-blind, parallel group comparison study, and the optimal concentration is determined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DE-089 ophthalmic solution | |
| DRUG | DE-089 ophthalmic solution | |
| DRUG | Placebo ophthalmic solution |
Timeline
- Primary completion
- 2006-07-01
- First posted
- 2010-08-26
- Last updated
- 2014-08-13
- Results posted
- 2014-08-08
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01189032. Inclusion in this directory is not an endorsement.